Trials / Terminated
TerminatedNCT01232881
Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer
Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 27 (actual)
- Sponsor
- Hoosier Cancer Research Network · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a tumor and serum collection study for patients with advanced breast cancer receiving treatment with lonafarnib.
Detailed description
OUTLINE: This is a multi-center study. Sample Collection: * Tumor sample * Serum sample Treatment Regimen: * All registered patients must be planning treatment with lonafarnib
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Tumor Sample | Tumor sample submission can consist of a fresh frozen tissue sample or a formalin-fixed paraffin embedded tissue block. |
| PROCEDURE | Serum Sample | Serum is to be collected prior to the initiation of lonafarnib treatment and 28 days after the last dose of lonafarnib. |
Timeline
- Start date
- 2009-08-01
- Primary completion
- 2010-11-01
- Completion
- 2010-11-01
- First posted
- 2010-11-02
- Last updated
- 2011-04-28
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01232881. Inclusion in this directory is not an endorsement.